These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20658904)

  • 1. Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2010 Aug; 4(4):435-44. PubMed ID: 20658904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
    Elborn JS; Henig NR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
    Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
    Pesaturo KA; Horton ER; Belliveau P
    Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled aztreonam lysine: an evidence-based review.
    Hutchinson D; Barclay M; Prescott WA; Brown J
    Expert Opin Pharmacother; 2013 Oct; 14(15):2115-24. PubMed ID: 23992352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Assael BM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
    J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aztreonam lysine for inhalation solution: in cystic fibrosis.
    Plosker GL
    Drugs; 2010 Oct; 70(14):1843-55. PubMed ID: 20836577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.
    Wainwright CE; Quittner AL; Geller DE; Nakamura C; Wooldridge JL; Gibson RL; Lewis S; Montgomery AB
    J Cyst Fibros; 2011 Jul; 10(4):234-42. PubMed ID: 21441078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosolized antibiotics in cystic fibrosis: an update.
    Fiel SB
    Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aztreonam lysine for inhalation: new formulation of an old antibiotic.
    Zeitler K; Salvas B; Stevens V; Brown J
    Am J Health Syst Pharm; 2012 Jan; 69(2):107-15. PubMed ID: 22215356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.
    Heirali AA; Workentine ML; Acosta N; Poonja A; Storey DG; Somayaji R; Rabin HR; Whelan FJ; Surette MG; Parkins MD
    Microbiome; 2017 May; 5(1):51. PubMed ID: 28476135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of nebulised aztreonam lysine (AZLI) in aztreonam hypersensitive patients.
    Whitaker P; Etherington C; Williams K; Conway S; Peckham D
    J Cyst Fibros; 2012 Jul; 11(4):353. PubMed ID: 22341263
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
    Ballmann M; Smyth A; Geller DE
    Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?
    Bos AC; van Holsbeke C; de Backer JW; van Westreenen M; Janssens HM; Vos WG; Tiddens HA
    PLoS One; 2015; 10(3):e0118454. PubMed ID: 25734630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
    Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ
    Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled aztreonam.
    O'Sullivan BP; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 May; 9(5):357-8. PubMed ID: 20431562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.